Behaviors and Mental Disorders

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Rare Diseases

Aggression

Fibromatosis, Aggressive

Dermoid Cyst

Fibroma

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Desmoid Tumor

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Imatinib Mesylate

Vactosertib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Vactosertib 200 mg PO BID 5 days on / 2 days off in combination with imatinib 400 mg PO QD daily

Imatinib

Hyunjoo Kim, MS

Hyosong Kim

Hyosong Kim, PHD

Sunjin Hwang, MD

Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy

This is an open-label, multi-center, randomized controlled study to evaluate the safety and efficacy of vactosertib 200 mg BID in combination with imatinib versus imatinib alone.

Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared With Imatinib Monotherapy

To evaluate the progression-free survival (PFS) of vactosertib and imatinib combination compared with imatinib alone up to 2 years. The subject will be assessed until disease progression is observed or death, which comes first. The disease progression will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria. The date of progression will be determined by a blinded, independent, central radiologic review (BICR).

MedPacto, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF)	NCT06219733	Dermoid	Vactosertib Imatinib	18 Years -	MedPacto, Inc.
Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF)	NCT06219733	Dermoid	Vactosertib Imatinib	18 Years -	MedPacto, Inc.

Spots Global Cancer Trial Database for dermoid

Every month we try and update this database with for dermoid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dermoid

Every month we try and update this database with for dermoid cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dermoid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.